Crinetics Pharmaceuticals (CRNX) Other Non-Current Liabilities (2024 - 2026)

Crinetics Pharmaceuticals' Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $4.9 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 178.78% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $4.9 million (up 178.78% YoY), while the FY2025 annual figure was $3.2 million, up 290.83% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $4.9 million, up from $3.2 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $4.9 million in Q1 2026, with the low at $202000.0 in Q2 2024.
• The 3-year median for Other Non-Current Liabilities is $2.1 million (2025), against an average of $2.1 million.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities surged 1055.45% in 2025, then jumped 178.78% in 2026.
• Crinetics Pharmaceuticals' Other Non-Current Liabilities stood at $829000.0 in 2024, then surged by 290.83% to $3.2 million in 2025, then jumped by 52.04% to $4.9 million in 2026.
• Business Quant data shows CRNX's Other Non-Current Liabilities at $4.9 million in Q1 2026, $3.2 million in Q4 2025, and $2.9 million in Q3 2025.